## PATENT COOPERATION TREATY



# **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

Anslation internat	PATENT COOPER P(		ATY	PCT/EP20(
ANTERNAT	TIONAL PRELIMINA		ATION REPO	RT
	(PCT Article 3	5 and Rule 70)		
Applicant's or agent's file reference 0000054204	FOR FURTHER ACT			mittal of Internated (Form PCT/IPEA
International application No. PCT/EP2003/014880	International filing date 24 December 2003	(day/month/year)	Priority date (day	· •
International Patent Classification (IPC) or C12N 1/04, 9/96, 9/78, 9/88			1 Vo January	2003 (08,01,200
Applicant	BASF AKTIENGE	SELLSCHAFT		
<ol> <li>This international preliminary example and is transmitted to the applicant</li> <li>This REPORT consists of a total of this report is also accompate amended and are the basis if 70.16 and Section 607 of the three annexes consist of a section for a sec</li></ol>	according to Article 36.  of 5 sheets, ir  anied by ANNEXES, i.e., sh for this report and/or sheets he Administrative Instruction	cluding this cover s cets of the descriptic containing rectifica as under the PCT),	heet. on, claims and/or d	trawings which have
This report contains indications report      Basis of the report	-	*	<b>***</b>	
II Priority  III Non-establishmen	nt of opinion with regard to r	ovelty inventive st	en and industrial a	nnlicahilitu
IV Lack of unity of in			-p and madamin aj	, p. 1040
V Reasoned statement citations and expla	ent under Article 35(2) with anations supporting such sta	egard to novelty, in tement	ventive step or ind	ustrial applicability
VI Certain documents	s cited			
VII Certain defects in	the international application	ı		
VIII Certain observation	ons on the international appl	cation		
Yes - Called a language of the second			A 17 1	
Date of submission of the demand 13 May 2004 (13.05		Date of completion of 25	of this report May 2005 (25.	.05.2005)
Name and mailing address of the IPBA/E	P	Authorized officer		

International application No.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/EP2003/014880

I. Basi	s of the r	eporé							
1. Wit	h regard t	o the clements of the international application:*							
	the inte	ernational application as originally filed							
	the des	scription;							
	pages	, as originally filed							
	pages	, filed with the demand							
	pages	, filed with the letter of							
X	the cla								
2_,3	pages								
	pages	, as originally filed , as amended (together with any statement under Article 19							
	pages	, filed with the demand							
	pages	1-14 , filed with the letter of09 March 2005 (09.03.2005)							
	the dra								
	pages	1/0.4/0							
	pages	, as originary more							
	pages	, filed with the demand							
	4	, filed with the letter of							
		ence listing part of the description:							
	pages	, as originally filed							
	pages pages	, filed with the demand							
	pugoo	, filed with the letter of							
1 11153	e elemen	to the language, all the elements marked above were available or furnished to this Authority in the language in which and application was filed, unless otherwise indicated under this item.  which is:							
	the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).								
		guage of publication of the international application (under Rule 48.3(b)).							
L	the language of the translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/ or 55.3).								
3. With preli	ununary e	to any nucleotide and/or amino acid sequence disclosed in the international application, the international xamination was carried out on the basis of the sequence listing:							
	contained in the international application in written form.								
		egether with the international application in computer readable form.							
		ed subsequently to this Authority in written form.							
		and subsequently to this Authority in computer readable form.							
	interna	atement that the subsequently furnished written sequence listing does not go beyond the disclosure in the tional application as filed has been furnished,							
	The sta	atement that the information recorded in computer readable form is identical to the written sequence listing has arnished.							
4.	The an	nendments have resulted in the cancellation of:							
		the description, pages							
		the claims, Nos.							
		the drawings, sheets/fig							
5.	This rep	port has been established as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**							
111 111	acement s is report 70.17).	sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to as "originally filed" and are not annexed to this report since they do not contain amendments (Rule 70.16							
** Any 1	** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.								

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/EP 03/14880

v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
1.	Statement						
	Novelty (N)	Claims	1, 5	YES			
		Claims	2-4, 6-14	NO			
	Inventive step (IS)	Claims	1; 5	YES			
		Claims	2-4, 6-14	NO			
	Industrial applicability (IA)	Claims	1-14	YES			
		Claims		NO			

#### 2. Citations and explanations

- 1. The present application relates to a method for conserving/stabilising micro-organisms having nitrile hydratase or nitrilase enzyme activity. An aldehyde, preferably benzaldehyde (example 3) or 2-chlorobenzaldehyde (example 4), is used as a stabiliser.
- 2. D1: US-A-4 900 672 (YAMADA HIDEAKI ET AL) 13 February 1990 (1990-02-13)
  - D2: DE 198 48 129 A (BASF AG) 20 April 2000 (2000-04-20)
- 3. Novelty
- 3.1 D1 discloses a method for conserving the nitrile hydratase activity in Pseudomonas. Inter alia, glyoxalic acid or other acids with aldehyde groups are proposed as stabilisers (column 2, line 65 column 3, line 42; claim 5). Nitriles and cyanide compounds are also proposed as stabilising additives (column 3, line 2 and line 17). The compounds can be used as stabilisers alone or in combination (column 2, line 68). The conserving effect of the glyoxalic acid is shown (table 3). The bacteria cells can be

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

present in suspension or immobilised.

Claims 2-4, 6-8, 13 and 14 are not novel over D1, since glyoxalic acid and other acids with aldehyde groups as disclosed in D1 (column 3, lines 28-29) are covered by the definition of claim 2 ("substituted or unsubstituted (...) C1-C10 alkyl"). Claims 9-12 are not novel either since they relate to a preparation with nitrile hydratase.

- 3.2 Furthermore, claim 13 is not novel over D2 since the latter also proposes the addition of aldehydes to the reaction mixture, albeit not for the purpose of conserving the enzyme activity (page 5, lines 13-18; claim 12). The feature "storage until use as per step c)" is not suitable, however, for delimiting the subject matter of claim 13 over D2, since the term "storage" is unclear with respect to a time limit.
- 3.3 Claim 5 relates specifically to substituted or unsubstituted benzaldehydes which are not disclosed as stabilisers in any of the citations. The claim is therefore novel.

The conservation of the nitrilase activity was not disclosed in D1. Claim 1 can therefore be considered novel.

4. Inventive step

Since none of the citations proposes the use of benzaldehydes for stabilising enzymes contained in micro-organisms, claim 5 can be considered inventive.

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/14880

Although the use of aldehydes for stabilising nitrile hydratase is known (D1), it cannot be considered obvious that this conservation method can also be used on the nitrile enzyme activity. Claim 1 therefore meets the inventive step requirements of PCT Article 33(3).